[go: up one dir, main page]

AR067602A1 - SULFONAMIDE AS TRPM8 MODULATORS - Google Patents

SULFONAMIDE AS TRPM8 MODULATORS

Info

Publication number
AR067602A1
AR067602A1 ARP080103108A ARP080103108A AR067602A1 AR 067602 A1 AR067602 A1 AR 067602A1 AR P080103108 A ARP080103108 A AR P080103108A AR P080103108 A ARP080103108 A AR P080103108A AR 067602 A1 AR067602 A1 AR 067602A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
optionally substituted
alkoxycarbonyl
substituents
Prior art date
Application number
ARP080103108A
Other languages
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39772848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR067602A1 publication Critical patent/AR067602A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1) donde A es CR5 o N; B es CR6 o N; con la condicion de que A y B son C(R5) y C(R6) respectivamente, cuando G es S(O)2; Y es (i) H; (ii) isopropenilo; (iii) alquilcarbonilo C1-6 sustituido de manera opcional con 1 a 3 sustituyentes fluor; (iv) cicloalquilcarbonilo C3-6 (v) fenilcarbonilo sustituido de manera opcional con uno a tres sustituyentes seleccionados de manera independiente entre alquilo C1-4, fluor, o cloro; (vi) fenilcarbonilo sustituido con trifluormetilo y opcionalmente un sustituyente adicional seleccionado entre trifluormetilo, cloro, fluor, o alquilo C1-4 (vii) heteroarilo sustituido de manera opcional con uno a dos sustituyentes seleccionados de manera independiente entre cloro, fluor, bromo, trifluormetilo, alcoxi C1-4, hidroxi, alquilo C1-4, alcoxicarbonilo C1-3, alquiltio C1-3, ciano, amino, alquilamino C1-3, o dialquilamino C1-3; (viii) heteroarilo benzo-fusionado sustituido de manera opcional con uno a dos sustituyentes seleccionados de manera independiente entre cloro, fluor, bromo, trifluormetilo, alquilo C1-4, alcoxi C1-4, hidroxi, alcoxicarbonilo C1-4, alquiltio C1-3, ciano, amino, alquilamino C1-3, o dialquilamino C1-3; (ix) bromo; (x) cloro; (xi) fluor; (xii) yodo; (xiii) ciano; (xiv) formilo; (xv) alquilo C1-6 sustituido de manera opcional con 1 a 3 sustituyentes seleccionados de manera independiente entre hidroxi, fluor, o cloro; (xvi) C(OH) (alquilo C1-3)2, (xvii) cicloalquilo C3-6, (xviii) alquilo C1-2 sustituido con 1 sustituyente seleccionado de manera independiente entre alcoxicarbonilo C1-4, ciano, alquiltio C1-3, alcoxi C1-4, o NR7R8 donde R7 es hidrogeno, alquilo C1-4, alquilcarbonilo C1-3, o alquilsulfonilo C1-3 y R8 es hidrogeno o alquilo C1-4; o R7 y R8 se toman junto con el átomo de nitrogeno al cual están unidos para formar un anillo de 5 o 6 miembros que contiene en forma opcional un heteroátomo adicional seleccionado entre nitrogeno, oxigeno, o azufre; (xix) alcoxicarbonilo C1-4, (xx) alcoxi C1-3, (xxi) hidroxi; (xxii) arilo C6-10 sustituido de manera opcional con uno a tres sustituyentes seleccionados de manera independiente entre cloro, fluor, bromo, alcoxi C1-4, hidroxi, alcoxicarbonilo C1-3, alquiltio C1-3, ciano, amino, alquilamino C1-2, dialquilamino C1-2, o alquilo C1-6 sustituido de manera opcional con uno a tres sustituyentes halogeno; con la condicion de que no más de dos de los sustituyentes están seleccionados del grupo formado por alcoxicarbonilo C1-3, alquiltio C1-3, ciano, amino, alquilamino C1-2, dialquilamino C1-2, y alquilo C1-6 sustituido con uno a tres sustituyentes halogeno; (xxiii) NR9R10 donde R9 es hidrogeno, alquilo C1-4, alquilcarbonilo C1-3, o alquilsulfonilo C1-3 y R10 es hidrogeno o alquilo C1-4, o R9 y R10 se toman junto con el átomo de nitrogeno al cual están unidos para formar un anillo de 5 o 6 miembros que contiene en forma opcional un heteroátomo adicional seleccionado entre nitrogeno, oxígeno, o azufre; y donde ese anillo de 5 o 6 miembros está sustituido de manera opcional con un sustituyente alquilo C1-4 con la condicion de que cuando G es S y R10 es hidrogeno, R9 no es hidrogeno y alquilo C1-4; (xxiv) aminocarbonilo; (xxv) metilaminocarbonilo; (xxvi) dimetilaminocarbonilo; o (xxvii) arilhidroxialquilo C1-3; R1es (i) CF3, (ii) alquilo C1-6 sustituido de manera opcional con 1 sustituyente seleccionado entre alquilsulfonilo C1-3, alcoxicarbonilo C1-4, formulo, hidroxi, carboxi, trifluormetilo, alcoxi C1-4, alquiltio C1-3, bromo, ciano, R11, o R12; (iii) aril-alquilo C1-2 donde el anillo del grupo arilo está sustituido de manera opcional con 1 a 3 sustituyentes seleccionados de manera independiente entre alquilo C1-4, fluor, cloro, trifluormetilo, hidroxi, alcoxi C1-4, alcoxicarbonilo C1-4, o carboxi; con la condicion de que no más de dos de los sustituyentes están seleccionados del grupo formado por trifluormetilo, alcoxicarbonilo C1-4, y carboxi; (iv) heteroaril-alquilo C1-6 donde el anillo del grupo heteroarilo está unido a través de un heteroátomo de nitrogeno y está seleccionado entre imidazolilo, triazolilo, o tetrazolilo; y donde el grupo imidazolilo está sustituido de manera opcional con 1 sustituyente seleccionado entre alquilo C1-4, fluor, cloro, trifluormetilo, hidroxi, alcoxi C1-4, alcoxicarbonilo C1-4, carboxi, aminometilo, metilamino-metilo, o dimetilamino-metilo; e imidazolilo está sustituido de manera opcional con un sustituyente adicional seleccionado entre alquilo C1-4, fluor, o cloro; (v) cicloalquilo C3-8; o ciclohexilo sustituido en la posicion 4 con un sustituyente seleccionado del grupo formado por ciano, alcoxicarbonilo C1-4, carboxi, aminocarbonilo, alquilaminocarbonilo C1-3, di-alquilo C1-3-aminocarbonilo, amino-metilo, metilamino-metilo, dimetilamino-metilo, R11, y R12, (vi) cicloalquilo C5-6 benzo-fusionado ligado en la porcion benzo del sistema anular, y donde la porcion cicloalquilo C5-6 del cicloalquilo C5-6 benzofusionado está sustituido de manera opcional con amino, alquilo C1-3-amino, o di-alquilo C1-3-amino; (vii) fenilo sustituido con 3- o 4-imidazolilo, donde el punto de union del imidazolilo es a través de un heteroátomo de nitrogeno; y donde el imidazolilo está sustituido de manera opcional e independiente con uno a dos sustituyentes seleccionados del grupo formado por alquilo C1-3, 2-ciano, cloro, bromo, amino-alquilo C1-2, alquilo C1-2-amino-alquilo C1-2, y di-alquilo C1-2-amino-alquiloC1-2 donde di-alquilo C1-3 se toma en forma opcional junto con el átomo de nitrogeno al cual está unido para formar un anillo de 5 o 6 miembros que contiene en forma opcional un heteroátomo adicional seleccionado entre nitrogeno, oxigeno, o azufre; y donde el anillo formado por di-alquilo C1-3amino está sustituido de manera opcional con alquilo C1-3 con la condicion de que no más de uno de los sustituyentes es amino-alquilo C1-3, alquilo C1-2-amino-alquilo C1-2, o di-alquilo C1-2-amino-aIquilo C1-2, (viii) fenilo sustituido de manera opcional con uno a tres sustituyentes seleccionados de manera independiente entre alquilo C1-4 sustituido de manera opcional con uno a tres sustituyentes cloro o fluor o un sustituyente hidroxi, cloro, fluor, bromo, alcoxi C1-4, trifluormetoxi, 3- o 4-feniloxi, 3- o 4-heteroariloxi donde el anillo heteroarilo es un anillo de 6 miembros que contiene miembros anulares de carbono y 1 o 2 miembros anulares del heteroátomo de nitrogeno, alquilsulfonilo C1-3, alcoxicarbonilo C1-4, alquiltio C1-3, hidroxi, carboxi, ciano, nitro, 3- o 4-heteroarilo donde dicho heteroarilo no es imidazolilo, alquilcarbonilo C1-3, aminocarbonilo, alquilaminocarbonilo C1-3, dialquilaminocarbonilo C1-3, alquilsulfonilaminocarbonilo C1-3, dialquilaminosulfonilo C1-3, P(O)(Oalquilo C1-3)2, P(O)(OH)2, SO3H, C(O)NHOH, C(=N)NH2, C(=NOH)NH2, C(=N(metilcarboniloxi))NH2, ni SO2NH2; con la condicion de que no más de dos de los sustituyentes están seleccionados del grupo formado por trifluormetoxi, 3- o 4-feniloxi sustituido, 3- o 4-heteroariloxi, alquilsulfonilo C1-3, alcoxicarbonilo C1-4, alquiltio C1-3, carboxi, ciano, 3- o 4-heteroarilo, alquilcarbonilo C1-3, aminocarbonilo, alquilaminocarbonilo C1-3, dialquilaminocarbonilo C1-3, alquilsulfonilaminocarbonilo C1-3, dialquilaminosulfonilo C1-3, y P(O)(Oalquilo C1-3)2 y no más de uno de los sustituyentes está seleccionado del grupo formado por -P(O)(OH)2, -SO3H, carboxi, C(O)NHOH, C(=N)NH2, C(=NOH)NH2, C(=N(alquilcarboniloxi C1-3))NH2, y -SO2NH2 donde el feniloxi está sustituido de manera opcional con uno a dos sustituyentes seleccionados de manera independiente del grupo formado por metilo y fluor; y donde el sustituyente heteroarilo está sustituido de manera opcional e independiente con uno a dos sustituyentes seleccionados del grupo formado por alquilo C1-3, trifluormetilo, trifluormetoxi, ciano, amino, metilamino, dimetilamino, cloro, bromo, carboxi, alcoxicarbonilo C1-2, alcoxicarbonilmetilo C1-2, carboximetilo, amino-alquil C1-2, alquilo C1-2-amino-alquilo C1-2, y di-alquilo C1-2-amino-alquilo-C1-2; con la condicion de que no más de uno de los sustituyentes está seleccionado del grupo formado por carboxi, alcoxicarbonilo C1-2, alcoxicarbonilmetilo C1-2, carboximetilo, amino-alquilo C1-2, alquilo C1-2amino-alquilo C1-2, y di-alquilo C1-2-amino-alquilo C1-2, (ix) naftilo sustituido de manera opcional con un sustituyente seleccionado del grupo formado por hidroxi, cloro, fluor, bromo, alcoxicarbonilo C1-4, y carboxi; (x) arilo C6-10 sustituido con fenilo sustituido de manera opcional con uno a dos sustituyentes seleccionados entre cloro, fluor, alcoxi C1-4, alcoxicarbonilo C1-4, carboxi, hidroxi, o alquilo C1-3, (xi) fenilo sustituido con R11 o R12 en la posicion 3 o 4, y opcionalmente un sustituyente adicional seleccionado entre fluor cloro o alquilo C1-3, (xii) piridin-3-ilo sustituido en un átomo de carbono que no es el que está adyacente al carbono que porta S(O)2 con un sustituyente seleccionado entre N-imidazolilo, oxadiazolilo, tiazolilo, R11, o R12 donde piridin-3-ilo está sustituido de manera opcional con un sustituyente adicional seleccionado entre fluor, cloro, o alquilo C1-3 y además, donde el grupo N-imidazolilo está sustituido de manera opcional con uno a dos sustituyentes, y los grupos oxadiazolilo y tiazolilo están sustituidos de manera opcional con un sustituyente, estando dicho(s) sustituyente(s) seleccionado(s) de manera independiente del grupo formado por alquilo C1-4, trifluormetilo, ciano, amino, metilamino, dimetilamino, cloro, bromo, carboxi, alcoxicarbonilo C1-2, alcoxicarbonilmetilo C1-2, carboximetilo, amino-aIquiIo C1-2, alquilo C1-2-amino-alquilo C1-2, y di-alquilo C1-2-amino-alquilo C1-2; con la condicion de que no más de uno de los sustituyentes está seleccionado del grupo formado por carboxi, alcoxicarbonilo C1-2, alcoxicarbonilmetilo C1-2, carboximetilo, trifluormetilo, ciano, amino-alquilo C1-2, alquilo C1-2amino-alquilo C1-2 y di-alquilo C1-2-amino-alquilo C1-2, (xiii) imidazolilo suClaim 1: A compound of the formula (1) wherein A is CR5 or N; B is CR6 or N; with the proviso that A and B are C (R5) and C (R6) respectively, when G is S (O) 2; Y is (i) H; (ii) isopropenyl; (iii) C1-6 alkylcarbonyl optionally substituted with 1 to 3 fluorine substituents; (iv) C3-6 cycloalkylcarbonyl (v) phenylcarbonyl optionally substituted with one to three substituents independently selected from C1-4 alkyl, fluorine, or chlorine; (vi) phenylcarbonyl substituted with trifluoromethyl and optionally an additional substituent selected from trifluoromethyl, chlorine, fluorine, or C1-4alkyl (vii) heteroaryl optionally substituted with one to two substituents independently selected from chlorine, fluorine, bromine, trifluoromethyl , C1-4 alkoxy, hydroxy, C1-4 alkyl, C1-3 alkoxycarbonyl, C1-3 alkylthio, cyano, amino, C1-3 alkylamino, or C1-3 dialkylamino; (viii) benzo-fused heteroaryl optionally substituted with one to two substituents independently selected from chlorine, fluorine, bromine, trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 alkoxycarbonyl, C1-3 alkylthio , cyano, amino, C1-3 alkylamino, or C1-3 dialkylamino; (ix) bromine; (x) chlorine; (xi) fluorine; (xii) iodine; (xiii) cyano; (xiv) formyl; (xv) C1-6 alkyl optionally substituted with 1 to 3 substituents independently selected from hydroxy, fluorine, or chlorine; (xvi) C (OH) (C1-3 alkyl) 2, (xvii) C3-6 cycloalkyl, (xviii) C1-2 alkyl substituted with 1 substituent independently selected from C1-4 alkoxycarbonyl, cyano, C1-3 alkylthio , C1-4 alkoxy, or NR7R8 where R7 is hydrogen, C1-4 alkyl, C1-3 alkylcarbonyl, or C1-3 alkylsulfonyl and R8 is hydrogen or C1-4 alkyl; or R7 and R8 are taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered ring that optionally contains an additional heteroatom selected from nitrogen, oxygen, or sulfur; (xix) C1-4 alkoxycarbonyl, (xx) C1-3 alkoxy, (xxi) hydroxy; (xxii) C6-10 aryl optionally substituted with one to three substituents independently selected from chlorine, fluorine, bromine, C1-4 alkoxy, hydroxy, C1-3 alkoxycarbonyl, C1-3 alkylthio, cyano, amino, C1 alkylamino -2, C1-2 dialkylamino, or C1-6 alkyl optionally substituted with one to three halogen substituents; with the proviso that no more than two of the substituents are selected from the group consisting of C1-3 alkoxycarbonyl, C1-3 alkylthio, cyano, amino, C1-2 alkylamino, C1-2 dialkylamino, and C1-6 alkyl substituted with one to three halogen substituents; (xxiii) NR9R10 where R9 is hydrogen, C1-4 alkyl, C1-3 alkylcarbonyl, or C1-3 alkyl sulfonyl and R10 is hydrogen or C1-4 alkyl, or R9 and R10 are taken together with the nitrogen atom to which they are attached to form a 5 or 6 member ring optionally containing an additional heteroatom selected from nitrogen, oxygen, or sulfur; and where that 5 or 6-membered ring is optionally substituted with a C1-4 alkyl substituent with the proviso that when G is S and R10 is hydrogen, R9 is not hydrogen and C1-4 alkyl; (xxiv) aminocarbonyl; (xxv) methylaminocarbonyl; (xxvi) dimethylaminocarbonyl; or (xxvii) C1-3 arylhydroxyalkyl; R1 is (i) CF3, (ii) C1-6 alkyl optionally substituted with 1 substituent selected from C1-3 alkylsulfonyl, C1-4 alkoxycarbonyl, formula, hydroxy, carboxy, trifluoromethyl, C1-4 alkoxy, C1-3 alkylthio, bromine, cyano, R11, or R12; (iii) aryl-C1-2 alkyl where the aryl group ring is optionally substituted with 1 to 3 substituents independently selected from C1-4 alkyl, fluorine, chlorine, trifluoromethyl, hydroxy, C1-4 alkoxy, C1 alkoxycarbonyl -4, or carboxy; with the proviso that no more than two of the substituents are selected from the group consisting of trifluoromethyl, C1-4 alkoxycarbonyl, and carboxy; (iv) heteroaryl-C 1-6 alkyl where the ring of the heteroaryl group is linked through a nitrogen heteroatom and is selected from imidazolyl, triazolyl, or tetrazolyl; and wherein the imidazolyl group is optionally substituted with 1 substituent selected from C 1-4 alkyl, fluorine, chloro, trifluoromethyl, hydroxy, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, carboxy, aminomethyl, methylamino methyl, or dimethylamino methyl ; and imidazolyl is optionally substituted with an additional substituent selected from C1-4 alkyl, fluorine, or chlorine; (v) C3-8 cycloalkyl; or cyclohexyl substituted at position 4 with a substituent selected from the group consisting of cyano, C1-4 alkoxycarbonyl, carboxy, aminocarbonyl, C1-3 alkylaminocarbonyl, di-C1-3-aminocarbonyl, amino-methyl, methylamino-methyl, dimethylamino- methyl, R11, and R12, (vi) benzo-fused C5-6 cycloalkyl linked in the benzo portion of the ring system, and where the C5-6 cycloalkyl portion of the benzofused C5-6 cycloalkyl is optionally substituted with amino, C1 alkyl -3-amino, or di-C 1-3 alkyl amino; (vii) phenyl substituted with 3- or 4-imidazolyl, where the point of attachment of the imidazolyl is through a nitrogen heteroatom; and wherein the imidazolyl is optionally and independently substituted with one to two substituents selected from the group consisting of C1-3 alkyl, 2-cyano, chloro, bromine, amino-C1-2 alkyl, C1-2 alkyl-amino-C1 alkyl -2, and di-C1-2-alkyl-C1-2-alkyl where di-C1-3 alkyl is optionally taken together with the nitrogen atom to which it is attached to form a 5 or 6-membered ring containing optionally an additional heteroatom selected from nitrogen, oxygen, or sulfur; and where the ring formed by di-C 1-3 alkyl is optionally substituted with C 1-3 alkyl with the proviso that no more than one of the substituents is C 1-3 alkyl, C 1-2 alkyl amino C1-2, or di-C1-2-amino-aC1-2 alkyl, (viii) phenyl optionally substituted with one to three substituents independently selected from C1-4 alkyl optionally substituted with one to three substituents chlorine or fluorine or a hydroxy, chlorine, fluorine, bromine, C1-4 alkoxy, trifluoromethoxy, 3- or 4-phenyloxy, 3- or 4-heteroaryloxy substituent wherein the heteroaryl ring is a 6-membered ring containing carbon ring members and 1 or 2 annular members of the nitrogen heteroatom, C1-3 alkylsulfonyl, C1-4 alkoxycarbonyl, C1-3 alkylthio, hydroxy, carboxy, cyano, nitro, 3- or 4-heteroaryl wherein said heteroaryl is not imidazolyl, C1- alkylcarbonyl 3, aminocarbonyl, C1-3 alkylaminocarbonyl, C1-3 dialkylaminocarbonyl, alkylsulfonylaminocar C1-3 bonyl, C1-3 dialkylaminosulfonyl, P (O) (C1-3alkyl) 2, P (O) (OH) 2, SO3H, C (O) NHOH, C (= N) NH2, C (= NOH ) NH2, C (= N (methylcarbonyloxy)) NH2, or SO2NH2; with the proviso that no more than two of the substituents are selected from the group consisting of trifluoromethoxy, 3- or 4-substituted phenyloxy, 3- or 4-heteroaryloxy, C1-3 alkylsulfonyl, C1-4 alkoxycarbonyl, C1-3 alkylthio, carboxy, cyano, 3- or 4-heteroaryl, C1-3 alkylcarbonyl, aminocarbonyl, C1-3 alkylaminocarbonyl, C1-3 dialkylaminocarbonyl, C1-3 alkylsulfonylaminocarbonyl, C1-3 dialkylaminosulfonyl, and P (O) (C1-3 alkyl) and no more than one of the substituents is selected from the group consisting of -P (O) (OH) 2, -SO3H, carboxy, C (O) NHOH, C (= N) NH2, C (= NOH) NH2, C (= N (C1-3 alkylcarbonyloxy)) NH2, and -SO2NH2 where phenyloxy is optionally substituted with one to two substituents independently selected from the group consisting of methyl and fluorine; and wherein the heteroaryl substituent is optionally and independently substituted with one to two substituents selected from the group consisting of C1-3 alkyl, trifluoromethyl, trifluoromethoxy, cyano, amino, methylamino, dimethylamino, chlorine, bromine, carboxy, C1-2 alkoxycarbonyl, C1-2 alkoxycarbonylmethyl, carboxymethyl, amino C1-2 alkyl, C1-2 alkyl-C1-2 amino-alkyl, and di-C1-2-amino-C1-2 alkyl; with the proviso that no more than one of the substituents is selected from the group consisting of carboxy, C1-2 alkoxycarbonyl, C1-2 alkoxycarbonylmethyl, carboxymethyl, C1-2 amino-alkyl, C1-2 alkyl-C1-2 alkyl, and di-C1-2-alkyl-C1-2-alkyl, (ix) naphthyl optionally substituted with a substituent selected from the group consisting of hydroxy, chlorine, fluorine, bromine, C1-4 alkoxycarbonyl, and carboxy; (x) C6-10 aryl substituted with phenyl optionally substituted with one to two substituents selected from chloro, fluorine, C1-4 alkoxy, C1-4 alkoxycarbonyl, carboxy, hydroxy, or C1-3 alkyl, (xi) substituted phenyl with R11 or R12 in position 3 or 4, and optionally an additional substituent selected from chlorine fluorine or C1-3alkyl, (xii) pyridin-3-yl substituted on a carbon atom that is not the one adjacent to the carbon that S (O) 2 carrier with a substituent selected from N-imidazolyl, oxadiazolyl, thiazolyl, R11, or R12 where pyridin-3-yl is optionally substituted with an additional substituent selected from fluorine, chlorine, or C1-3 alkyl and furthermore, where the N-imidazolyl group is optionally substituted with one to two substituents, and the oxadiazolyl and thiazolyl groups are optionally substituted with a substituent, said substituent (s) being selected independently. from the group consisting of C1-4 alkyl, tri fluoromethyl, cyano, amino, methylamino, dimethylamino, chloro, bromine, carboxy, C1-2 alkoxycarbonyl, C1-2 alkoxycarbonylmethyl, carboxymethyl, amino C1-2 alkyl, C1-2 alkyl C1-2 alkyl, and di- C1-2 alkyl-C1-2 alkyl; with the proviso that no more than one of the substituents is selected from the group consisting of carboxy, C1-2 alkoxycarbonyl, C1-2 alkoxycarbonylmethyl, carboxymethyl, trifluoromethyl, cyano, C1-2 amino-alkyl, C1-2 amino-C1-alkyl -2 and di-C1-2-alkyl-C1-2-alkyl, (xiii) imidazolyl su

ARP080103108A 2007-07-18 2008-07-18 SULFONAMIDE AS TRPM8 MODULATORS AR067602A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95045607P 2007-07-18 2007-07-18

Publications (1)

Publication Number Publication Date
AR067602A1 true AR067602A1 (en) 2009-10-14

Family

ID=39772848

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103108A AR067602A1 (en) 2007-07-18 2008-07-18 SULFONAMIDE AS TRPM8 MODULATORS

Country Status (27)

Country Link
US (3) US8153682B2 (en)
EP (1) EP2183239B1 (en)
JP (1) JP5539868B2 (en)
KR (1) KR101538391B1 (en)
CN (1) CN101801949B (en)
AR (1) AR067602A1 (en)
AU (3) AU2008275927B8 (en)
BR (1) BRPI0815096A2 (en)
CA (1) CA2693159C (en)
CL (1) CL2008002132A1 (en)
CO (1) CO6251375A2 (en)
CR (1) CR11284A (en)
EA (1) EA201070158A1 (en)
EC (1) ECSP109921A (en)
GT (1) GT201000015A (en)
IL (1) IL203295A (en)
JO (1) JO2853B1 (en)
MX (1) MX2010000690A (en)
MY (1) MY153971A (en)
NI (1) NI201000013A (en)
NZ (1) NZ582555A (en)
PA (1) PA8790401A1 (en)
TW (1) TWI446909B (en)
UA (1) UA99624C2 (en)
UY (1) UY31239A1 (en)
WO (1) WO2009012430A1 (en)
ZA (1) ZA201001157B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216547B2 (en) * 2008-07-18 2012-07-10 Janssen Pharmaceutica Nv Radiolabelled TRP M8 receptor ligands
CA2741751C (en) * 2008-10-27 2017-05-09 Alza Corporation Extended release oral acetaminophen/tramadol dosage form
CA2747662A1 (en) * 2008-12-18 2010-07-15 Janssen Pharmaceutica Nv Sulfonamides as trpm8 modulators
JP2012512879A (en) 2008-12-18 2012-06-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Sulfamide as a TRPM8 modulator
JP5756457B2 (en) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
CN102427810A (en) * 2009-05-01 2012-04-25 拉夸里亚创药株式会社 Sulfamoylbenzoic acid derivatives as TRPM8 antagonists
TW201103941A (en) * 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
TW201105681A (en) * 2009-06-10 2011-02-16 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
ES2352398B1 (en) * 2009-06-25 2011-09-29 Institut Univ. De Ciencia I Tecnologia S.A. N-FENETILSULFONAMIDAS-N-SUBSTITUTED FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY.
US20120122920A1 (en) * 2009-06-26 2012-05-17 Josep Castells Boliart Libraries of n-substituted-n-phenylethylsulfonamides for drug discovery
SG177434A1 (en) 2009-06-29 2012-02-28 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
US20120122710A1 (en) * 2009-07-01 2012-05-17 Josep Castells Boliart Libraries of n-substituted-n-phenylethylsulfonamides for the identification of biological and pharmacological activity
JP5770198B2 (en) * 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ．ベー． Phenoxy-substituted pyrimidines as opioid receptor modulators
DE102010002558A1 (en) 2009-11-20 2011-06-01 Symrise Ag Use of physiological cooling agents and agents containing such agents
WO2012042915A1 (en) * 2010-10-01 2012-04-05 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists
US8618150B2 (en) 2010-12-09 2013-12-31 Janssen Pharmaceutica, Nv Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators
WO2012083246A1 (en) 2010-12-17 2012-06-21 Agios Pharmaceuticals, Inc. Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
MX336022B (en) 2010-12-21 2016-01-06 Agios Pharmaceuticals Inc Bicyclic pkm2 activators.
US8906384B2 (en) * 2010-12-22 2014-12-09 The United States Of America As Represented By The Secretary Of Agriculture Antiviral activity of bovine type III interferon against foot-and-mouth disease virus
TWI549947B (en) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 Therapeutic compounds and compositions
EP2481727A1 (en) 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
ES2588752T3 (en) * 2011-03-16 2016-11-04 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds that have antagonistic TRPM8 activity
WO2012151440A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
PT2704721T (en) 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
EP2606888A1 (en) 2011-12-19 2013-06-26 Dompe' S.P.A. Trpm8 antagonists
AU2012357747B2 (en) 2011-12-19 2017-09-07 Dompe' Farmaceutici S.P.A. TRPM8 antagonists
WO2014042238A1 (en) 2012-09-14 2014-03-20 田辺三菱製薬株式会社 Sulfonamide compound
JP5985453B2 (en) * 2012-09-14 2016-09-06 田辺三菱製薬株式会社 Pharmaceutical composition
EP2774919A1 (en) * 2013-03-06 2014-09-10 Pharmeste S.R.L. In Liquidazione Novel sulfonamide TRPA1 receptor antagonists
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AU2014270339A1 (en) * 2013-05-24 2015-10-08 Nestec S.A. Treatment or prevention of depression using Menthol and/or Icilin
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
CN105705610B (en) * 2013-08-23 2018-01-30 巴斯夫欧洲公司 Compound with end heteroaryl cyano group ethenylidene and its application in organic solar batteries
ME03399B (en) 2014-06-23 2020-01-20 Dompe Farm Spa 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and asthma
SI3307271T1 (en) 2015-06-11 2023-11-30 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
KR102655928B1 (en) 2015-06-23 2024-04-09 깃세이 야쿠힌 고교 가부시키가이샤 Pyrazole derivative, or its pharmacologically acceptable salt
JP7096152B2 (en) 2015-10-06 2022-07-05 オーラ・インコーポレーテッド Transient Receptor Potential Ion Channel Subfamily M Member 8 (TRPM8) Antagonists and Methods of Use
EP3184524A1 (en) 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
CA3038916A1 (en) * 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
US11434220B2 (en) 2017-08-31 2022-09-06 Basf Se Use of physiological cooling active ingredients, and compositions comprising such active ingredients
US12269816B2 (en) 2019-04-30 2025-04-08 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Benzothiophene compound, preparation method therefor and use thereof
CN116096715A (en) * 2020-07-06 2023-05-09 泰科根公司 Beneficial benzothiophene compositions for mental disorders or enhancement
RU2756587C9 (en) * 2021-02-12 2021-10-12 Акционерное общество "Отисифарм" Derivatives of 2-acetamido-6-hydroxy-benzothiophene and their pharmacologically acceptable salts with antiviral activity
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725141D0 (en) * 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Benzenesulfonamide compounds
DE10215321A1 (en) 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh New nucleic acid encoding Trpp8 splice variants, useful for diagnosis of prostatic cancer, and to screen for diagnostic or therapeutic agents, also related proteins
WO2006040103A1 (en) 2004-10-13 2006-04-20 Bayer Healthcare Ag Use of cold menthol receptor modulators for the treatment of respiratory disorders
EP1802600A1 (en) * 2004-10-13 2007-07-04 Bayer HealthCare AG Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonits for the treatment of urological disorders
CA2617042A1 (en) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
WO2007017094A1 (en) * 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted benzyloxy-phenylmethylcarbamate derivatives
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
WO2007017092A1 (en) * 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
US7897781B2 (en) * 2006-05-10 2011-03-01 Janssen Pharmaceutica Nv Cold menthol receptor-1 antagonists

Also Published As

Publication number Publication date
JP2010533734A (en) 2010-10-28
CR11284A (en) 2010-08-18
CA2693159A1 (en) 2009-01-22
AU2016204436A1 (en) 2016-07-21
MY153971A (en) 2015-04-30
US8153682B2 (en) 2012-04-10
US8809327B2 (en) 2014-08-19
UY31239A1 (en) 2009-03-31
GT201000015A (en) 2012-03-12
ZA201001157B (en) 2011-04-28
WO2009012430A1 (en) 2009-01-22
NZ582555A (en) 2012-06-29
CL2008002132A1 (en) 2009-03-06
EA201070158A1 (en) 2010-08-30
AU2008275927B2 (en) 2014-08-07
KR101538391B1 (en) 2015-07-21
AU2008275927A1 (en) 2009-01-22
MX2010000690A (en) 2010-06-25
UA99624C2 (en) 2012-09-10
BRPI0815096A2 (en) 2015-07-14
IL203295A (en) 2015-09-24
NI201000013A (en) 2010-07-22
TWI446909B (en) 2014-08-01
CO6251375A2 (en) 2011-02-21
US20140315899A1 (en) 2014-10-23
US20120190674A1 (en) 2012-07-26
EP2183239A1 (en) 2010-05-12
EP2183239B1 (en) 2012-08-22
CA2693159C (en) 2016-05-24
ECSP109921A (en) 2010-02-26
CN101801949B (en) 2014-09-24
PA8790401A1 (en) 2009-03-31
JP5539868B2 (en) 2014-07-02
JO2853B1 (en) 2015-03-15
TW200918045A (en) 2009-05-01
US20090264474A1 (en) 2009-10-22
AU2008275927B8 (en) 2014-08-14
CN101801949A (en) 2010-08-11
KR20100049598A (en) 2010-05-12
AU2014203797A1 (en) 2014-07-31
US9434711B2 (en) 2016-09-06

Similar Documents

Publication Publication Date Title
AR067602A1 (en) SULFONAMIDE AS TRPM8 MODULATORS
PE20130375A1 (en) TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINE COMPOUNDS, C-MET INHIBITORS AND COMPOSITIONS THEREOF
AR078463A1 (en) COMPOSITION AND METHOD TO CONTROL PESTS OF ARTROPODES
AR067759A1 (en) USEFUL PIRAZOL COMPOUNDS AS MODULATORS OF RAF ENZYME ASSOCIATED WITH ABNORMAL CELLULAR GROWTH
WO2008108256A1 (en) Light-emitting device material and light-emitting device
PE20130155A1 (en) ARYLETINYL DERIVATIVES
PE20090068A1 (en) FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR GAMMA
AR067945A1 (en) FUSIONED BICYCLE PYRIMIDINS
AR046020A1 (en) GLUCOCORTICOID MIMETICS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
UY31014A1 (en) DERIVATIVES OF FTALAZINONA
AR044519A1 (en) DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
ES2422204T3 (en) Novel derivatives of imidazolidin-2-one as selective androgen receptor modulators (SARMS)
AR049443A1 (en) PIRROLPIRIDINE DERIVATIVES
TW201129675A (en) Light-emitting organic thin film, composition, organic electroluminescent device, display apparatus, and lighting apparatus
AR057914A1 (en) ORGANIC COMPOUNDS OF SULFUR AND ITS USE
AR063979A1 (en) DIAZEPAM OREXINE RECEIVER ANTAGONISTS REPLACED
PE20141041A1 (en) COMPOUNDS, METHODS AND PARASITICIDE FORMULATIONS
CO6231035A2 (en) NOVEDOUS HETEROMONOCICLIC COMPOUND THAT HAS SUPERIOR PROPERTIES AS A PHARMACEUTICAL AGENT
AR084766A1 (en) BICYCLE COMPOUND TO MODULATE THE RECEPTORS COUPLED TO PROTEIN G
UA115661C2 (en) Tetrazolinone compounds and its use as pesticides
PE20121534A1 (en) NEW MAITANSINOIDS AND THE USE OF SUCH MAITANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY
CR8827A (en) FUSED HETEROCICLIC COMPOUND
AR066954A1 (en) DERIVATIVES OF 7- ALQUINIL-1,8- NAFTIRIDONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
AR076610A1 (en) SPIRO EPOXIDE COMPOUNDS AS INTERMEDIARIES
PE20090703A1 (en) NEW PROCEDURE FOR THE SYNTHESIS OF STRONTIUM RANELATE AND ITS HYDRATES

Legal Events

Date Code Title Description
FB Suspension of granting procedure